Feature | Antiplatelet and Anticoagulation Therapies | May 12, 2017

Delayed Use of Blood Thinners in AFib Patients Increased Dementia Risk

First large scale study of 76,000 patients shows impact of antiplatelet and anticoagulant agents on dementia risks

anticoagulants increase dementia risks

May 12, 2017 – A new study found that dementia rates increase with delays in starting anticoagulation treatment for atrial fibrillation (AFib or AF). The large study included more than 76,230 AF patients with no prior history of dementia that were treated with an antiplatelet or warfarin. The results were presented at Heart Rhythm 2017, the Heart Rhythm Society’s 38th Annual Scientific Sessions, and show that warfarin, in particular, can increase the risk of dementia long-term.

AF, the most common heart arrhythmia, affects more than 2.7 million American adults and has been known to increase a person’s risk of stroke and death. Anticoagulants and antiplatelet agents, especially warfarin, are powerful stroke prevention interventions and are now being prescribed to millions worldwide.[1] However, there is often a delay in starting anticoagulants after the initial AF diagnosis due to a variety of reasons, including low risk of stroke, exploration of other treatment options like aspirin, older age, multiple comorbidities, and other factors.

The study included 76,230 AF patients who had no prior history of dementia or prior use of an anticoagulation treatment. Of these, 26,189 patients were ultimately treated with an antiplatelet (n=21,781) or warfarin anticoagulation (n=4,408). Time from AF diagnosis to the use of an antiplatelet agent or anticoagulation was studied at immediate start (less than 30 days from diagnosis), and delayed (after one year). The authors note that CHADS2 Vasc score can be used to identify those at highest risk of cognitive decline with a delay in therapy. The risk of dementia with a delay in low risk CHADS2 Vasc patients was 30 percent but increased significantly to 136 percent in high-risk CHADS2 Vasc patients. The authors also found that when the time period of delays were analyzed as a spectrum from less than 30 days, 31 days to one year, one to three years and longer than three years, there was a linear risk of dementia risk with the delays in warfarin initiation.

“Our results reinforce the importance of starting anticoagulation treatment as early as possible after being diagnosed with atrial fibrillation. We saw for the first time that waiting even just 30 days to initiate anticoagulation treatment can increase a patient’s long-term risk of developing dementia,” said T. Jared Bunch, M.D., director of heart rhythm research at Intermountain Medical Center Heart Institute and medical director for heart rhythm services for the Intermountain Healthcare system. “We want to ensure we’re doing everything possible to limit the risk of brain injury for our patients and our study not only shows the importance of early therapy but also shows the very limited role, if any, of aspirin for stroke prevention. In this study,the benefit was derived from using warfarin and we hope that newer anticoagulants that perform better than warfarin and are easier to start and use will further improve dementia risk.”

The authors of the study called for additional studies to fully understand how the risk of dementia increases over a longer period of time. They have recently launched a prospective study using dabigatran versus warfarin that will closely study cognitive changes over a two-year period. The growing use of these newer treatments like direct oral anticoagulants such as dabigatran, apixaban and rivaroxaban, are providing patients with more effective options and should also be studied to determine the risk of dementia.

Related Content:

Long-term Anti-clotting/antiplatelet Drug Combo in AFib Patients May Raise Risk of Dementia

Atrial Fibrillation Patients at Increased Risk of Dementia Regardless of Anticoagulation Use

Dementia Risk Increased for Afib Patients on Long-Term Warfarin Treatment

Researchers Find Link Between Early-Stage Brain and Heart Disease

Vascular Disease after Age 80 Associated with Greater Dementia Risk

Advantages and Disadvantages of Novel Oral Anticoagulants


For more information: www.HRSonline.org, www.hrssessions.org


1. A. Di Minno, G. Spadarella, T. Antonella, G. Di Minno. “Ensuring medication adherence with direct oral anticoagulant drugs. Lessons from adherence with vitamin K antagonists (VKAs).” Thrombosis Research, 2014, 133(5). DOI: 10.1016/j.thromres.2014.01.016 

2. T. Jared Bunch, Heidi T. May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler, John D. Day, Victoria Jacobs, Charles Mallender, Jeffrey S. Osborn, Scott M. Stevens, J. Peter Weiss and Scott C. Woller. HRS Heart Rhythm 2017 meeting session, “Anticoagulation for Atrial Fibrillation: Current Strategies and Device-Based Approaches: Dementia Rates Increase With Delays In Initiation of Anticoagulation Treatment for Atrial Fibrillation.” Presented May 12, 2017.

Related Content

Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients
News | Antiplatelet and Anticoagulation Therapies | September 09, 2019
Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary syndrome and a planned...
Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies familiar to...
Fragmin (dalteparin sodium) injection was cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Fragmin (dalteparin sodium) injection is now cleared by the FDA for use in pediatric patients. It was initially approved by the FDA in 1994 for adults and is a type of heparin.

Technology | Antiplatelet and Anticoagulation Therapies | May 17, 2019
May 17, 2019 — The U.S.
PhaseBio Receives FDA Breakthrough Therapy Designation for Ticagrelor Reversal Agent
Technology | Antiplatelet and Anticoagulation Therapies | April 30, 2019
PhaseBio Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people sto
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT Study. The clinical...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the...
Overlay Init